Contact
Please use this form to send email to PR contact of this press release:
Biomed Industries Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Agonist for Obesity at ENDO 2025
TO:
Michael Willis
Biomed Industries, Inc.
+1 800-824-5135